New hope for tough leukemias: revumenib trial opens

NCT ID NCT06229912

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called revumenib in 40 people with leukemia that has come back or not responded to treatment. The leukemia must have certain genetic changes that turn on HOX genes. The goal is to see if revumenib can safely control the disease. Participants take the drug by mouth and are monitored for side effects and response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: revumenib (SNDX-5613)
What this could lead to: If successful, revumenib could offer a new treatment option for people with certain hard-to-treat leukemias that have not responded to standard therapy.
What could go wrong: This is an early Phase 2 trial with only 40 participants, so results may not apply to all patients. The drug may cause side effects or fail to control the leukemia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HOX GENE LEUKEMIA

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.